Further analysis of lipid metabolomics is granted to validate our findings and for a more comprehensive comparison between lipid metabolic disturbances found in the plasma of FMR1 premutation carriers and FXTAS patients. This evidence concerns the gene FMR1 and fragile X-associated tremor/ataxia syndrome.